MET and lung carcinoma: Lung cancer patients with MET exon 14 mutations responded modestly to single-agent or combination immune checkpoint inhibitors (objective response rate: 17%, 95% CI: 6%-36%) [55], and didn’t seem to benefit from immunotherapy [56].